Evidence map›Paper›PMID 29758119›Full record

ArticleCancer science2018

Loss of protein phosphatase 6 in mouse keratinocytes enhances K-ras

Koreyuki Kurosawa, Yui Inoue, Yoichiro Kakugawa, Yoji Yamashita, Kosuke Kanazawa, Kazuhiro Kishimoto, Miyuki Nomura, Yuki Momoi, Ikuro Sato, Natsuko Chiba and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Oncogenic K-RasFEBS open bio · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Koreyuki KurosawaDivision of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Yui InoueDivision of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Yoichiro KakugawaDivision of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Yoji YamashitaDivision of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Kosuke KanazawaDivision of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Kazuhiro KishimotoDivision of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Miyuki NomuraDivision of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Yuki MomoiDivision of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Ikuro SatoDivision of Pathology, Miyagi Cancer Center, Miyagi, Japan.
Natsuko ChibaDepartment of Cancer Biology, Institute of Development, Aging and Cancer, Tohoku University, Miyagi, Japan.
Mai SuzukiDepartment of Biological Science, Graduate School of Humanities and Sciences, Nara Women's University, Nara, Japan.
Honami OgohDepartment of Biological Science, Graduate School of Humanities and Sciences, Nara Women's University, Nara, Japan.
Hidekazu YamadaDivision of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Koh MiuraDivision of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Toshio WatanabeDepartment of Biological Science, Graduate School of Humanities and Sciences, Nara Women's University, Nara, Japan.
Nobuhiro TanumaDivision of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Masahiro TachiDepartment of Plastic and Reconstructive Surgery, Tohoku University Hospital, Miyagi, Japan.
Hiroshi ShimaDivision of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.ORCID http://orcid.org/0000-0002-0857-8929
Miyagi Prefectural Hospital Organization · JPNara Women's University · JPTohoku University · JPTohoku University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we address the function of protein phosphatase 6 (PP6) loss on K-ras-initiated tumorigenesis in keratinocytes. To do so, we developed tamoxifen-inducible double mutant (K-ras

Indexed as

AnimalsCarcinogenesisKeratinocytesMiceMice, Mutant StrainsPhosphoprotein PhosphatasesProto-Oncogene Proteins p21(ras)Skin NeoplasmsHras protein, mousePhosphoprotein Phosphatasesprotein phosphatase 6Proto-Oncogene Proteins p21(ras)AKT pathwayK-rasmouse keratinocyteprotein phosphatase 6tumor initiation and promotion

Identifiers

PMID29758119
PMCPMC6029815
OpenAlexW2804293304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.